(Press-News.org) In an era of $1,000-a-pill medications, a new approach may be needed to finance an emerging breed of highly expensive pharmaceuticals and vaccines, according to a new RAND Corporation analysis.
In other industries, it is common for suppliers to encourage investment through approaches such as equipment leases or supplier-financed credit. Health care could learn from such approaches, according to Dr. Soeren Mattke, lead author of the analysis and a senior scientist at RAND, a nonprofit research organization.
Instead of paying upfront for the cost of a treatment -- $20 billion to vaccinate Brazil's 203 million people against dengue fever, for example -- a health system could issue debt instruments to the manufacturer. Those instruments could be structured as bonds, as mortgages or as lines of credit. Terms and interest rates would vary.
It's not unprecedented, even in the healthcare industry, researchers say. When hospitals need expensive equipment, they might lease it, or the supplier might offer a financial arrangement to help with the upfront cost.
"So it's not far-fetched for pharmaceutical companies to offer payers financial arrangements to ease some of the up-front costs," said Mattke, the managing director of RAND Health Advisory Services.
New approaches to pay for health care may be needed as the pharmaceutical industry has turned its attention to specialty breakthrough drugs.
"Pharmaceutical companies are focusing on highly targeted medicines to treat rarer conditions and smaller numbers of patients," said Mattke. And when the drug offers a cure, the companies must make their investment pay off over a shorter period of time.
"In order to get to a blockbuster, drug companies may need to charge $100,000 per course of treatment and give a medication to 10,000 people," said Mattke. "In this scenario, you have a drug that is highly effective, a good value for the money, and yet you have payers saying that they cannot afford it because of the front-loaded nature of the cost."
One drug that captures the tension between immediate budget concerns and the long-term value of treatment is Sovaldi, a drug made by Gilead Scientific that cures hepatitis C in 95 percent of patients, albeit at $1,000 per pill, or $84,000 for a typical course of treatment in the United States.
The short-term impact on healthcare budgets can put this cure out of reach. Express Scripts, a pharmacy benefits manager, estimates that prescription drug spending on hepatitis C will increase 1,800 percent by 2017.
But Sovaldi might pay for itself in, say, 10 years in savings from reduced hospital stays and liver transplant costs. "So stretch those payments over the time period in which the savings would materialize," Mattke said.
There are caveats to such financial schemes, write Mattke and co-author Emily Hoch. For example, companies would have to show that real-world outcomes were as good as clinical trial results in order to receive full payment.
If the drug or vaccine didn't work as well as promised, repayment would be lowered accordingly. A neutral third party would need to design and evaluate the payment arrangement and evaluate the effectiveness on a real-world sample of patients.
Such financial arrangements could work well in countries with national health systems or at least stable insurance coverage. They would be more difficult in the United States, where patients change health plans often.
"It's possible, in theory, in the United States if you have a transfer mechanism," Mattke said. "If I get cleared from hepatitis C from one insurer, the debt would have to travel with me to my next insurer." The authors are currently working on a paper to explore options for how a long-term repayment system could operate in the United States.
INFORMATION:
The perspective, "Borrowing for the Cure: Debt Financing of Breakthrough Treatments," is available at http://www.rand.org. The research underlying the paper was conducted in RAND Health Advisory Services, the consulting practice of RAND Health that engages in work for the private sector and produces results that are disseminated broadly in the public interest. Support was provided by RAND internal funding.
RAND Health is the nation's largest independent health policy research program, with a broad research portfolio that focuses on health care costs, quality and public health preparedness, among other topics.
ANN ARBOR, Mich. -- The anti-inflammatory class of drugs NSAIDs have shown great promise in preventing cancers including colon, esophagus and skin. However, they can increase the risks of heart attacks, ulcers and rare but potentially life-threatening bleeds.
A new study suggests there may be ways to reduce these dangerous side effects.
Collaborators from the University of Michigan, the National Cancer Institute and the University of Alabama looked at naproxen, which is known to have a lower cardiovascular risk than other NSAIDs. Naproxen, like most NSAIDs and aspirin, ...
An Antarctic octopus that lives in ice-cold water uses an unique strategy to transport oxygen in its blood, according to research published in Frontiers in Zoology. The study suggests that the octopus's specialized blood pigments could help to make it more resilient to climate change than Antarctic fish and other species of octopus.
The Antarctic Ocean hosts rich and diverse fauna despite inhospitable temperatures close to freezing. While it can be hard to deliver oxygen to tissues in the cold due to lower oxygen diffusion and increased blood viscosity, ice-cold waters ...
Studying the intricate fractal patterns on the surface of cells could give researchers a new insight into the physical nature of cancer, and provide new ways of preventing the disease from developing.
This is according to scientists in the US who have, for the first time, shown how physical fractal patterns emerge on the surface of human cancer cells at a specific point of progression towards cancer.
Publishing their results today, 11 March, in the Institute of Physics and Germany Physical Society's New Journal of Physics, they found that the distinctive repeating fractal ...
Voices in people's heads are far more varied and complex than previously thought, according to new research by Durham and Stanford universities, published in The Lancet Psychiatry today.
One of the largest and most detailed studies to date on the experience of auditory hallucinations, commonly referred to as voice hearing, found that the majority of voice-hearers hear multiple voices with distinct character-like qualities, with many also experiencing physical effects on their bodies.
The study also confirmed that both people with and without psychiatric diagnoses hear ...
During pregnancy, the mother supplies the fetus with nutrients and oxygen via the placenta. If placental development is impaired, this may lead to growth disorders of the embryo or to life-threatening diseases of the mother such as preeclampsia, a serious condition involving high blood pressure and increased urinary protein excretion. Now, Dr. Katharina Walentin and Professor Kai Schmidt-Ott of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch have discovered a new molecular signaling pathway which regulates the development of the placenta. Perturbations ...
In a study published in The Lancet on March 10, researchers from Brigham and Women's Hospital (BWH) report that patients with a genetic sensitivity to warfarin - the most widely used anticoagulant for preventing blood clots - have higher rates of bleeding during the first several months of treatment and benefited from treatment with a different anticoagulant drug. The analyses from the TIMI Study Group, suggest that using genetics to identify patients who are most at risk of bleeding, and tailoring treatment accordingly, could offer important safety benefits, particularly ...
VANCOUVER, Wash.--Washington State University researchers have found a mechanism in the brain that facilitates the pathologically powerful role of memory in drug addiction. Their discovery opens a new area of research for targeted therapy that would alter or disable the mechanism and make drug addiction less compulsive.
Turning off the mechanism is "diminishing the emotional impact or the emotional content of the memory, so it decreases the motivation to relapse," said Barbara Sorg, a professor of neuroscience at Washington State University, Vancouver. Her findings appear ...
Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have uncovered new clues about the risk of cancer from low-dose radiation, which in this research they define as equivalent to 100 millisieverts or roughly the dose received from ten full-body CT scans.
They studied mice and found their risk of mammary cancer from low-dose radiation depends a great deal on their genetic makeup. They also learned key details about how genes and the cells immediately surrounding a tumor (also called the tumor microenvironment) affect cancer ...
La Jolla, Calif., March 9, 2015 - Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have discovered a mechanism that explains why some breast cancer tumors respond to specific chemotherapies and others do not. The findings highlight the level of glutamine, an essential nutrient for cancer development, as a determinant of breast cancer response to select anticancer therapies, and identify a marker associated with glutamine uptake, for potential prognosis and stratification of breast cancer therapy.
"Our study indicates that a protein called RNF5 ...
McGill researchers have discovered, for the first time, the importance of a key epigenetic regulator in the development of the hippocampus, a part of the brain associated with learning, memory and neural stem cells. Epigenetic regulators change the way specific genes function without altering their DNA sequence. By working with mutant mice as models, the research team, led by Prof. Xiang-Jiao Yang, of McGill's Goodman Cancer Center & Department of Medicine, McGill University Health Center, was able to link the importance of a specific epigenetic regulator known as BRPF1 ...
